UBS Group’s Keryx Biopharmaceuticals Inc KERX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q4 | – | Sell |
-51,534
| Closed | -$175K | – | 8600 |
|
|
2018
Q3 | $175K | Sell |
51,534
-11,030
| -18% | -$39.8K | ﹤0.01% | 5167 |
|
|
2018
Q2 | $235K | Sell |
62,564
-169,370
| -73% | -$825K | ﹤0.01% | 4833 |
|
|
2018
Q1 | $949K | Buy |
231,934
+129,296
| +126% | +$602K | ﹤0.01% | 3753 |
|
|
2017
Q4 | $477K | Sell |
102,638
-2,664
| -3% | -$14.7K | ﹤0.01% | 4328 |
|
|
2017
Q3 | $747K | Sell |
105,302
-82,848
| -44% | -$596K | ﹤0.01% | 3933 |
|
|
2017
Q2 | $1.36M | Sell |
188,150
-76,438
| -29% | -$478K | ﹤0.01% | 3350 |
|
|
2017
Q1 | $1.63M | Buy |
264,588
+28,416
| +12% | +$156K | ﹤0.01% | 3127 |
|
|
2016
Q4 | $1.38M | Sell |
236,172
-55,585
| -19% | -$304K | ﹤0.01% | 3266 |
|
|
2016
Q3 | $1.55M | Sell |
291,757
-56,387
| -16% | -$304K | ﹤0.01% | 3075 |
|
|
2016
Q2 | $2.31M | Sell |
348,144
-40,391
| -10% | -$226K | ﹤0.01% | 2657 |
|
|
2016
Q1 | $1.81M | Sell |
388,535
-75,870
| -16% | -$303K | ﹤0.01% | 2763 |
|
|
2015
Q4 | $2.35M | Sell |
464,405
-12,203
| -3% | -$58K | ﹤0.01% | 2651 |
|
|
2015
Q3 | $1.68M | Buy |
476,608
+226,629
| +91% | +$1.52M | ﹤0.01% | 2898 |
|
|
2015
Q2 | $2.5M | Sell |
249,979
-86,383
| -26% | -$926K | ﹤0.01% | 2768 |
|
|
2015
Q1 | $4.28M | Buy |
336,362
+165,539
| +97% | +$2.13M | ﹤0.01% | 2202 |
|
|
2014
Q4 | $2.42M | Buy |
+170,823
| New | +$2.65M | ﹤0.01% | 2715 |
|
UBS Group's KERX Position: Q4 2018 in Review
UBS Group sold out of Keryx Biopharmaceuticals Inc (KERX) in Q4 2018, closing a stake of 51,534 shares — an estimated $175K sold.
UBS Group first reported a position in KERX in Q4 2014 and held it in 16 quarters. The position peaked at $4.28M in Q1 2015. 1 fund tracked by Wall St. Rank holds KERX as of Q4 2018.
- UBS Group reported no remaining Keryx Biopharmaceuticals Inc position as of Q4 2018 after selling out during the quarter.
- UBS Group sold 51,534 Keryx Biopharmaceuticals Inc shares in Q4 2018, an estimated $175K.
- UBS Group first reported a position in Keryx Biopharmaceuticals Inc in Q4 2014 and held it in 16 quarters.
- UBS Group's Keryx Biopharmaceuticals Inc position peaked at $4.28M in Q1 2015.
- 1 fund tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q4 2018.
Based on UBS Group's 13F filing for Q4 2018, filed 14 Feb 2019.